Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Lucas

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
Human Pathology|May 1, 2026
EWSR1-Rearranged Renal Neoplasia: Clinicopathologic and Molecular Characterization of 39 Cases from a Single InstitutionRobert G Colef, Ganesh P Pujari, Daniel R Sill, et al.
JAMA Oncology|December 8, 2016
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain MetastasesNolan Priedigkeit, Ryan J Hartmaier, Yijing Chen, et al.
Cancer Research Communications|October 3, 2022
BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcomaLisa M Maurer, Jessica D Daley, Elina Mukherjee, et al.
JNCI Cancer Spectrum|November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Nature Cancer|March 17, 2023
Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironmentSayali Onkar, Jian Cui, Jian Zou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
The Journal of Clinical Investigation|April 15, 2025
A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphomaHeejae Kang, Lisa M Maurer, Jing Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 TrialEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Nature Cancer|April 3, 2023
Publisher Correction: Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironmentSayali Onkar, Jian Cui, Jian Zou, et al.
Oncogene|August 18, 2019
MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor typesJ Randall McAuley, Kelly M Bailey, Prasanna Ekambaram, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Human Pathology|May 1, 2026
EWSR1-Rearranged Renal Neoplasia: Clinicopathologic and Molecular Characterization of 39 Cases from a Single InstitutionRobert G Colef, Ganesh P Pujari, Daniel R Sill, et al.
JAMA Oncology|December 8, 2016
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain MetastasesNolan Priedigkeit, Ryan J Hartmaier, Yijing Chen, et al.
Cancer Research Communications|October 3, 2022
BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcomaLisa M Maurer, Jessica D Daley, Elina Mukherjee, et al.
JNCI Cancer Spectrum|November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Nature Cancer|March 17, 2023
Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironmentSayali Onkar, Jian Cui, Jian Zou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
The Journal of Clinical Investigation|April 15, 2025
A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphomaHeejae Kang, Lisa M Maurer, Jing Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 TrialEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.
Nature Cancer|April 3, 2023
Publisher Correction: Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironmentSayali Onkar, Jian Cui, Jian Zou, et al.
Oncogene|August 18, 2019
MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor typesJ Randall McAuley, Kelly M Bailey, Prasanna Ekambaram, et al.
Pageof 12